/
Solventum Corporation ("Solventum," "we," "our," "us," or the "Company"), is a leading global healthcare company developing, manufacturing, and commercializing a broad portfolio of solutions that leverages deep material science, data science, and digital capabilities to address critical customer and patient needs. We constantly seek to enable the improvement of standards of care and move health…
$81.31
$0.39 (-0.48%)
EOD Jul 17, 2026
Margins and capital returns are both well above average: 26.20% operating margin, ROIC at 18.88%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue growth slowed to 0.9%, essentially flat. This is a business that needs a catalyst.
Free cash flow declined 101% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -$10M. The business is consuming cash, not generating it.
10.0x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$8.26B
▲ +0.9% YoY
Net Income (TTM)
$1.43B
▲ +224.8% YoY
Op. Margin
25.54%
▲ +13.6pp YoY
ROIC
17.57%
▲ +10.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$203M
▼ -101.2% YoY
Op. Cash Flow (TTM)
$151M
▼ -68.9% YoY
Net Debt
$4.73B
Cash & Equiv.
$561M
3Y CAGR: +0.8%
Continue Research
At a P/E of 10.0, Solventum (SOLV)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Solventum scores 39/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Solventum scores 39 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 25.5% operating margin and a 17.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SOLV's valuation and scores 39/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.